Anavex Life Sciences Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.33next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly131.7MTarget: Sufficient to fund operations for more than 3 years
Quarterly Net Loss Quarterly-5.7MTarget: Achieve profitability by 2027 or 2028
Research and Development Expenses Quarterly4.7MTarget: Maintain disciplined clinical spending
Watch Items
- Nasdaq Listing Compliance Plan SubmissionTrigger: Deadline of July 20, 2026Action: Submit a comprehensive plan to Nasdaq explaining how the company will regain compliance by filing its delayed Form 10-Q for the period ended March 31, 2026.
- EMA Re-examination of Blarcamesine Marketing Authorization ApplicationTrigger: CHMP final decision expected in the first half of 2026Action: Engage with the newly appointed EMA rapporteur and co-rapporteur to address points raised in the initial negative opinion.
- FDA Alignment on Alzheimer's Disease Development ProgramTrigger: Submission of existing Phase IIb/III data requested by the FDAAction: Submit requested clinical data to align on potential pathways towards a New Drug Application (NDA) in the U.S.
Research as of 19 Jun 2026